Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?
Authors:
Richard Češka
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
Published in:
Forum Diab 2017; 6(3): 109-114
Category:
Topic
Overview
The drugs of a novel class of hypolipidemic agents, PCSK9-inhibitors, are now approved for clinical use. In many EU countries, including Slovakia, these drugs are also available in clinical practice. Since this ”biological therapy” is admittedly costly, their administration is subject to restrictions that vary by country. Of the two molecules of PCSK9-inhibitors (evolocumab and alirocumab), we shall first focus on evolocumab and then in particular on the Fourier study. The Fourier study was presented at the congress of the American College of Cardiology in March 2017 It is truly a “mega-study” which involved more than 27 500 patients with a proven cardiovascular disease, who had been treated with statins and in spite of a maximum tolerated hypolipidemic therapy they had had LDL-C over 1.8 mmol/l or non-HDL-C over 2.6 mmol/l. They also had another significant cardiovascular risk factor. Further on they received a maximum statin (+ ezetimib) hypolipidemic therapy in combination with evolocumab or placebo. The results of the study were clearly positive. The primary target indicator decreased by 15%, the secondary (cardiovascular death, myocardial infarction and stroke) was reduced by 20%. Both the results were statistically significant. A marked decrease in LDL-C by almost 60% was recorded. The treatment was well tolerated and practically without adverse effects. Despite very favourable results we quite frequently see discussions to consider whether the achieved results are sufficient, or rather sufficiently convincing. This paper answers these questions clearly: YES. The therapy with evolocumab led to statistically and clinically significant reduction of cardiovascular events. The fact that the results equivalent to the historical studies with statins (e.g. “4S“) have not been reached is not difficult to explain. It also needs to be admitted that some of us, probably under the influence of really extraordinary effects of PCSK9-inhibitors, expected a miracle rather than a very positive outcome.
Key words:
evolocumab (Repatha), PCSK9-inhibitors, LDL-principle, LDL-cholesterol, Fourier Study
Sources
1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
2. Giugliano RP, Mach F, Zavitz K et al. Evaluation of cognitive function in a randomized trial of evolocumab. N Engl J Med 2017; 377: 633–643. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1701131>.
3. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
4. Giugliano RP, Cannon CP, Blazing MA et al. Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. J Am Coll Cardiol 2015; 65(Suppl 10): A4. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(15)60004–3>.
5. Nicholls SJ, Puri R, Anderson T et al. Eff ect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 2016; 316(22): 2373–2384. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.16951>.
6. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058.
7. Češka R (ed) et al. Familiární hypercholesterolémie. Triton: Praha 2015. ISBN 978–80–7387–843–6.
8. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013, 35(8): 1082–1098. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clinthera.2013.06.019>.
9. Češka R, Vrablík M. The authors of lipid guidelines are at odds with their own recommendations. Cor Vasa 2017; 59(4):e416–e417. Dostupné na WWW: <http://www.sciencedirect.com/science/article/pii/S0010865017300218>.
10. Baigent C, Blackwell L, Emberson J et al. [Cholesterol Treatment Trialists Collaborators]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
11. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – full report. J Clin Lipidol 2015; 9(2): 129–169. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2015.02.003>.
12. Jacobson TA, Maki KC, Orringer CE et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol 2015; 9 (6 Suppl): S1-S122.e121. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2015.09.002>. Erratum in J Clin Lipidol 2016; 10(1): 211.
13. Boekholdt SM, Hovingh GK, Mora S et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64(5): 485–494. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.02.615>.
14. Wiviott SD, Cannon CP, Morrow DA et al. Can low-density lipoprotein be too low? The safety and effi cacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46(8): 1411–1416. Erratum in J Am Coll Cardiol 2006 Jan 17;47(2): 472.
15. Giugliano RP, Wiviott SD, Blazing MA et al. Long-term safety and effi cacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecifi ed analysis of the IMPROVE-IT trial. JAMA Cardiol 2017; 2(5): 547–555. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2017.0083>.
16. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–1389.
17. [Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group]. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349–1357.
18. Orringer CE, Jacobson TA, Saseen JJ et al. Update on the use of PCSK9-inhibitors in adults: recommendations from an expert panel of the National Lipid Association. J Clin Lipidol 2017; 11(4):880–890. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2017.05.001>.
19. Lipinski MJ, Benedetto U, Escarcega RO et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2016; 37(6): 536–545. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv563>.
20. Koren MJ, Sabatine MS, Giugliano RP et al. Long-term low-density lipoprotein cholesterol-lowering effi cacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017; 2(6): 598–607. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2017.0747>.
21. Sabatine MS, et al. American College of Cardiology – 66th Annual Scientific Session Late-Breaking Clinical Trial. Washington, D.C. March 17, 2017. Oral presentation.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2017 Issue 3
Most read in this issue
- Rehabilitation in diabetic patients
- Management of cardiovascular risk in the light of current recommendations
- Diabetes mellitus and cerebrovascular diseases
- Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?